Partner Gregory Husisian is quoted in a Bloomberg article, “American CEOs Say They’re Ready to Bring Jobs Home If Nafta Dies,” about the potential collapse of the continent’s trade pact.
Husisian, who advises companies on how to hedge against NAFTA risk, says some may be more worried than they let on. Businesses with major fixed investments in Mexico, such as large factories, tend to be most concerned, he said, while those with more “mobile” assets, such as tool and die presses, are not as troubled by the prospect.
For the most part, he said, companies aren’t actively hedging much yet because “it looks like NAFTA will be around for a while.”
Husisian, who advises companies on how to hedge against NAFTA risk, says some may be more worried than they let on. Businesses with major fixed investments in Mexico, such as large factories, tend to be most concerned, he said, while those with more “mobile” assets, such as tool and die presses, are not as troubled by the prospect.
For the most part, he said, companies aren’t actively hedging much yet because “it looks like NAFTA will be around for a while.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”